Kewaunee Scientific Corporation (KEQU) Key Metrics
KEQU valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $95.3M
- Enterprise value
- $121.2M
- P/E (TTM)
- 11.9 10-yr median 13.8
- Forward P/E
- 7.7
- PEG ratio
- —
- Price / sales
- 0.3 10-yr median 0.4
- Price / book
- 1.3 10-yr median 1.4
- EV / EBITDA
- 5.5 10-yr median 7.1
- Dividend yield
- —
- Beta
- 0.76
KEQU key metrics, FY2017–FY2026
Fiscal year ended April 30, 2026 · U.S. dollarsKEQU valuation Price multiples at each fiscal year-end price.
KEQU returns How much profit the business earns on the capital it uses.
KEQU per-share figures Results divided by the shares outstanding at year-end.
KEQU financial health Debt, liquidity and how easily interest is covered.
KEQU efficiency & capital use Working capital cycle and where the cash goes.
KEQU valuation history
KEQU returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KEQU debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KEQU cash returned to shareholders
KEQU price vs earnings per share
KEQU key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $110.4M | $94.3M | $104.9M | $47.2M | $39.7M | $33.1M | $28.1M | $63.2M | $97.1M | $62.4M |
| Enterprise value | $129.0M | $129.6M | $92.6M | $52.0M | $102.9M | $44.1M | $37.6M | $63.5M | $93.7M | $56.9M |
| P/E ratio | 11.5 | 8.3 | 5.6 | 34.7 | — | — | — | 41.4 | 18.7 | 13.8 |
| Price / sales | 0.4 | 0.4 | 0.5 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.6 | 0.5 |
| Price / book | 1.5 | 1.5 | 1.9 | 1.3 | 1.1 | 0.8 | 0.7 | 1.3 | 2.0 | 1.4 |
| Price / free cash flow | 7.5 | 7.5 | 6.9 | — | — | — | 16.6 | — | — | 6.9 |
| Price / operating cash flow | 5.9 | 6.4 | 5.4 | — | — | 36.3 | 6.8 | 25.4 | 30.5 | 5.4 |
| EV / sales | 0.5 | 0.5 | 0.5 | 0.2 | 0.6 | 0.3 | 0.3 | 0.4 | 0.6 | 0.4 |
| EV / EBITDA | 5.4 | 5.7 | 5.1 | 6.4 | 112.3 | 96.0 | 133.7 | 13.6 | 7.8 | 6.2 |
| EV / free cash flow | 8.8 | 10.3 | 6.1 | — | — | — | 22.2 | — | — | 6.3 |
| Earnings yield | 8.7% | 12.1% | 17.9% | 2.9% | −15.1% | −10.9% | −16.4% | 2.4% | 5.3% | 7.2% |
| Free cash flow yield | 13.3% | 13.4% | 14.5% | −16.8% | −24.6% | −4.5% | 6.0% | −2.7% | −0.2% | 14.5% |
| Dividend yield | — | — | — | — | — | 0.3% | 3.7% | 3.2% | 1.8% | 2.5% |
| Shareholder yield (dividends + buybacks) | 0.6% | 1.7% | 1.9% | 0.0% | — | 0.3% | 3.8% | 3.2% | 1.8% | 2.5% |
| Share price at fiscal year-end | $37.01 | $31.67 | $35.70 | $16.25 | $14.26 | $12.00 | $10.23 | $22.63 | $34.95 | $22.90 |
| Per share | ||||||||||
| Revenue per share | $94.54 | $80.72 | $69.35 | $75.64 | $60.61 | $53.43 | $53.65 | $52.45 | $56.91 | $50.83 |
| Earnings per share | $3.22 | $3.83 | $6.38 | $0.47 | −$2.15 | −$1.31 | −$1.68 | $0.55 | $1.87 | $1.66 |
| Operating cash flow per share | $6.25 | $4.96 | $6.66 | −$1.31 | −$2.83 | $0.33 | $1.51 | $0.89 | $1.15 | $4.28 |
| Free cash flow per share | $4.93 | $4.24 | $5.17 | −$2.74 | −$3.52 | −$0.54 | $0.62 | −$0.62 | −$0.08 | $3.32 |
| Cash per share | $3.89 | $5.02 | $7.92 | $2.78 | $1.59 | $1.89 | $1.59 | $3.81 | $3.50 | $4.59 |
| Book value per share | $25.05 | $21.64 | $18.64 | $12.89 | $12.81 | $14.94 | $13.97 | $17.07 | $17.11 | $16.19 |
| Tangible book value per share | $15.40 | $11.46 | $18.64 | $12.89 | $12.81 | $14.94 | $13.97 | $17.07 | $17.11 | $16.19 |
| Dividends per share | — | — | — | — | — | $0.04 | $0.38 | $0.73 | $0.65 | $0.58 |
| Capex per share | $1.32 | $0.73 | $1.49 | $1.43 | $0.68 | $0.87 | $0.90 | $1.51 | $1.22 | $0.96 |
| Debt per share | $10.12 | $16.84 | $3.74 | $4.45 | $24.25 | $5.85 | $5.02 | $3.91 | $2.27 | $2.55 |
| Shares outstanding | 3.0M | 3.0M | 2.9M | 2.9M | 2.8M | 2.8M | 2.8M | 2.8M | 2.8M | 2.7M |
| Change in shares outstanding | +0.1% | +1.4% | +1.2% | +4.2% | +0.9% | +0.4% | −1.6% | +0.6% | +1.9% | +1.5% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 13.8% | 19.1% | 40.7% | 3.7% | −15.6% | −9.1% | −10.7% | 3.2% | 11.3% | 10.9% |
| Return on invested capital (ROIC) | 13.2% | 19.6% | 43.1% | 2.6% | −2.7% | −2.1% | −3.9% | 3.6% | 12.4% | 11.3% |
| Return on assets (ROA) | 5.2% | 6.9% | 14.8% | 1.1% | −5.8% | −4.2% | −5.4% | 1.8% | 6.3% | 5.9% |
| Return on tangible assets | 6.4% | 6.9% | 13.9% | 1.1% | −5.1% | −4.0% | −5.5% | 1.8% | 6.1% | 5.6% |
| Free cash flow margin | 5.2% | 5.2% | 7.5% | −3.6% | −5.8% | −1.0% | 1.1% | −1.2% | −0.1% | 6.5% |
| Income quality (OCF / net income) | 1.94 | 1.30 | 1.04 | −2.79 | — | — | — | 1.63 | 0.61 | 2.58 |
| Financial health | ||||||||||
| Total debt | $30.2M | $50.2M | $11.0M | $12.9M | $67.6M | $16.1M | $13.8M | $10.9M | $6.3M | $6.9M |
| Cash & short-term investments | $11.6M | $14.9M | $23.3M | $8.1M | $4.4M | $5.2M | $4.4M | $10.6M | $9.7M | $12.5M |
| Net debt | $18.6M | $35.2M | −$12.3M | $4.8M | $63.1M | $10.9M | $9.4M | $279,000 | −$3.4M | −$5.6M |
| Debt / equity | 0.40 | 0.78 | 0.20 | 0.35 | 1.89 | 0.39 | 0.36 | 0.23 | 0.13 | 0.16 |
| Debt / assets | 0.17 | 0.26 | 0.08 | 0.11 | 0.57 | 0.18 | 0.16 | 0.13 | 0.07 | 0.09 |
| Net debt / EBITDA | 0.78 | 1.55 | −0.68 | 0.59 | 68.92 | 23.84 | 33.58 | 0.06 | −0.28 | −0.60 |
| Current ratio | 2.18 | 2.20 | 2.37 | 2.20 | 2.17 | 1.77 | 2.00 | 2.00 | 2.30 | 2.22 |
| Quick ratio | 1.55 | 1.59 | 1.87 | 1.65 | 1.60 | 1.29 | 1.44 | 1.47 | 1.66 | 1.67 |
| Interest coverage | 4.3 | 5.5 | 10.2 | 2.1 | -4.1 | -3.4 | -4.8 | 5.8 | 30.4 | 22.4 |
| Working capital | $57.0M | $64.7M | $56.0M | $47.9M | $49.3M | $26.3M | $27.2M | $32.6M | $35.9M | $32.9M |
| Invested capital | $93.3M | $99.7M | $42.5M | $42.3M | $98.8M | $52.2M | $47.9M | $48.0M | $44.1M | $38.6M |
| Tangible asset value | $48.0M | $35.9M | $56.2M | $38.5M | $36.2M | $41.5M | $38.7M | $47.7M | $47.5M | $44.1M |
| Net current asset value | $3.9M | −$10.0M | $18.3M | $7.5M | $9.0M | $12.6M | $9.0M | $25.8M | $26.7M | $23.6M |
| Graham number | $42.63 | $43.17 | $51.74 | $11.65 | — | — | — | $14.50 | $26.82 | $24.56 |
| Graham net-net per share | −$10.25 | −$16.87 | −$3.80 | −$9.25 | −$9.06 | −$3.54 | −$4.42 | $1.67 | $2.23 | $2.25 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $108,000 | $1.0M | $2.0M | $1.8M | $1.6M |
| Share buybacks (net) | $671,000 | $1.6M | $2.0M | $0 | — | — | $14,000 | $0 | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | — | — | 132.8% | 34.6% | 34.8% |
| Dividends + buybacks / free cash flow | 4.6% | 12.6% | 13.2% | — | — | — | 62.4% | — | — | 17.3% |
| Capex / revenue | 1.4% | 0.9% | 2.1% | 1.9% | 1.1% | 1.6% | 1.7% | 2.9% | 2.1% | 1.9% |
| Capex / operating cash flow | 21.1% | 14.7% | 22.4% | — | — | 262.8% | 59.2% | 169.2% | 106.7% | 22.4% |
| Capex / depreciation | 0.63 | 0.46 | 1.40 | 1.45 | 0.69 | 0.89 | 0.93 | 1.64 | 1.23 | 0.97 |
| Stock-based compensation / revenue | 0.8% | 0.6% | 0.5% | 0.4% | 0.4% | 0.4% | 0.2% | 0.1% | 0.2% | 0.1% |
| R&D / revenue | 0.3% | — | 0.5% | 0.5% | 0.6% | 1.0% | 1.2% | 1.1% | 1.0% | 0.8% |
| SG&A / revenue | 22.6% | 21.2% | 18.5% | 13.5% | 15.8% | 17.8% | 17.6% | 15.7% | 14.5% | 14.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 78.4 | 81.5 | 81.6 | 83.8 | 94.7 | 75.4 | 75.9 | 82.1 | 72.2 | 76.0 |
| Days of inventory on hand | 57.4 | 56.9 | 51.2 | 45.3 | 50.9 | 47.1 | 47.8 | 52.5 | 47.2 | 49.8 |
| Days payables outstanding | 44.8 | 53.5 | 56.4 | 50.5 | 55.6 | 44.2 | 41.6 | 45.1 | 38.7 | 38.7 |
| Cash conversion cycle (days) | 91.0 | 85.0 | 76.5 | 78.6 | 89.9 | 78.3 | 82.1 | 89.5 | 80.7 | 87.2 |
| Receivables turnover | 4.66 | 4.48 | 4.47 | 4.36 | 3.86 | 4.84 | 4.81 | 4.45 | 5.05 | 4.80 |
| Payables turnover | 8.15 | 6.82 | 6.47 | 7.22 | 6.56 | 8.26 | 8.77 | 8.10 | 9.42 | 9.44 |
| Inventory turnover | 6.36 | 6.41 | 7.13 | 8.05 | 7.18 | 7.75 | 7.63 | 6.95 | 7.73 | 7.33 |
| Asset turnover | 1.51 | 1.46 | 1.61 | 1.85 | 1.62 | 1.70 | 1.72 | 1.71 | 1.92 | 1.81 |
| Average receivables | $60.6M | $53.7M | $45.6M | $50.4M | $43.8M | $30.5M | $30.7M | $33.0M | $31.3M | $28.9M |
| Average payables | $24.7M | $25.1M | $23.4M | $25.5M | $22.0M | $14.9M | $14.2M | $15.0M | $13.4M | $11.9M |
| Average inventory | $31.7M | $26.8M | $21.3M | $22.8M | $20.2M | $15.9M | $16.3M | $17.4M | $16.3M | $15.3M |
| Intangibles / total assets | 16.1% | 15.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KEQU's annual financial statements (latest annual report filed June 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KEQU valuation and financial ratios
At the end of fiscal 2026 (April 30, 2026), Kewaunee Scientific traded at 11.5 times earnings, against a 10-year median of 13.8. Based on the latest twelve months, the trailing P/E is 11.9 and the forward P/E is 7.7. Kewaunee Scientific earned a return on equity of 13.8% and a return on invested capital of 13.2% in fiscal 2026. It ended the year with $30.2 million of debt and $11.6 million in cash and short-term investments, net debt of $18.6 million. It returned $0.7 million to shareholders: $0 in dividends and $0.7 million in share buybacks, 5% of free cash flow. The share count rose 9.4% from 2.7M to 3.0M over 9 years.
See the KEQU income statement, the KEQU chart for price history, or the KEQU stock overview for the latest quote and news.
KEQU key metrics FAQ
What is Kewaunee Scientific's P/E ratio?
Kewaunee Scientific's trailing P/E ratio is 11.9 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 7.7. At the end of fiscal 2026 it was 11.5, compared with a 10-year median of 13.8.
What is Kewaunee Scientific's EV/EBITDA?
Kewaunee Scientific's enterprise value was 5.4 times EBITDA at the end of fiscal 2026 (enterprise value $129.0 million, EBITDA $23.9 million); the current EV/EBITDA is 5.5.
What is Kewaunee Scientific's return on equity?
Kewaunee Scientific's return on equity (ROE) was 13.8% in fiscal 2026: net income of $9.6 million on average shareholders' equity of $69.6 million.
What is Kewaunee Scientific's ROIC?
Kewaunee Scientific's return on invested capital was 13.2% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Kewaunee Scientific have?
Kewaunee Scientific had total debt of $30.2 million at the end of fiscal 2026, a debt-to-equity ratio of 0.40 and $18.6 million of net debt (0.78 times EBITDA).
Does Kewaunee Scientific buy back its shares?
Yes. Kewaunee Scientific spent $0.7 million on net share repurchases in fiscal 2026 Shares outstanding changed +0.1% over the year, to 3.0M..
What is Kewaunee Scientific's free cash flow yield?
Kewaunee Scientific generated $14.7 million of free cash flow in fiscal 2026, a free cash flow yield of 13.3% on its market value at year-end ($110.4 million).
What is Kewaunee Scientific's current ratio?
Kewaunee Scientific's current ratio was 2.18 at the end of fiscal 2026: current assets were 2.18 times current liabilities.